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T H E R O L E O F A T R I A L N A T R I U R E T I C PEPTIDE 
(ANP) IN CHRONIC L I V E R DISEASE 
A L E X A N D E R L . G E R B E S 
Department of Internal Mediane II, Klinikum Grosshadern, University of Munich, 81377 
Munich, Germany 
Abstract—The role of atrial natriuretic peptide (ANP) and potential defects of ANP in liver 
disease are reviewed. Patients with cirrhosis of the liver show no decrease of ANP plasma 
concentrations nor changes in the pattern of ANP immunoreactivity nor changes of splanchnic 
ANP clearance. The renal effects of exogenously administered as well as endogenously released 
ANP are blunted in cirrhosis, in particular in patients with ascites. This seems due to increased 
activity of sodium-retaining hormonal systems and changes of the renal ANP receptor status. 
Pharmacological inhibition of ANP-degradation or clearance may yield therapeutic potential. 
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1. FEATURES OF ANP 
The atrial natriuretic factor was identified in 1984 as a peptide hormone (hence the name atrial 
natriuretic peptide, ANP) with particular importance in the regulation of intravascular volume and 
blood vessel tonus (Cantin and Genest, 1986; Inagami, 1989; Lang et aL, 1987; Larose et aL, 1985; 
Needleman and Greenwald, 1986). Since little is known about the physiological role or pathophys-
iological importance of brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), the 
other recently discovered members of the natriuretic peptide family, this review will concentrate 
on ANP. Following appropriate stimulation, such as atrial distention (Gerbes et aL, 1986, 1988; 
Gerbes and Vollmar, 1988; Lang et aL, 1985), a 126 amino acid prohormone is released from the 
secretory granules of atrial myocytes and cleaved. This is followed by an increase of both clearance 
products, the C-terminal 28 amino acid as well as the N-terminal fragment in the plasma. The 
C-terminal fragment has been identified as a biologically active hormone, whereas a biological 
action of the N-terminal fragment is not generally accepted. While the heart is the major source 
of circulating ANP, synthesis of ANP has also been found in various extracardiac organs such as 
intestine, lung and thymus and organs of the reproductive system (Gerbes et aL, 1991a; Gutkowska 
and Nemer, 1989; Vollmar, 1990). Elimination of ANP from the circulation occurs by enzymatic 
degradation or binding to clearance receptors in several organs such as kidney, lung or liver (Gerbes 
Dedicated to Professor Dr G. Paumgartner on the occasion of his 60th birthday. 
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ance receptor. 
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and Vollmar, 1990). Liver and intestinal circulation contribute significantly to the extraction o f 
ANP with arterio-venous extraction ratios found between 28 and 75% (Gerbes and Vollmar, 1990; 
Gerbes et aL, 1992). There are two different types of ANP receptors: two kinds of biological-active 
(B)-receptors, coupled to guanylate cyclase, exhibiting a high affinity for C-terminal ANP and a 
clearance-receptor (C-receptor) binding C-terminal ANP with lower affinity but also binding 
truncated ANP analogs (Almeida et aL, 1989; Chinkers et aL, 1989; Kollenda et aL, 1991; Maack 
et aL, 1987; Wilcox et aL, 1991). The two B-receptor types exhibit different affinity to the members 
of the natriuretic peptide family ANP, BNP and CNP. Physiological changes of the intravascular 
volume, e.g. dehydration or sodium loading, can affect the density of B- and C-receptors for A N P 
to a different extent (Kollenda et aL, 1990). Thus, changes of ANP receptor status may constitute 
a way of regulating the ANP system. 
Major effects of ANP affect intravascular volume and pressure. Several of these biological 
activities are rather well described: relaxation of smooth muscle cells, suppression of renin and 
aldosterone synthesis and release, as well as various renal effects mediated by glomerular and 
tubular receptors resulting in natriuresis and diuresis. Recently, evidence has accumulated for 
biological actions in the reproductive and immune systems (Gutkowska and Nemer, 1989; Vollmar, 
1990). A physiological role of ANP in the regulation of intravascular volume and pressure is 
supported by various investigations employing blockade of ANP release, administration of specific 
antibodies or very low dose infusions of ANP. Transgenic mice overexpressing ANP and constantly 
exhibiting 10-fold elevated plasma concentrations show a markedly lower arterial blood pressure 
(Field et aL, 1991). 
2. ACTIONS OF ANP O N THE LIVER A N D HEPATIC C I R C U L A T I O N 
In the anesthetized dog, intraarterial bolus injections of ANP caused graded increases in hepatic 
arterial blood flow representing a vasodilation, comparable to the effects of isoprenaline. In 
contrast, there was no obvious effect on portal venous inflow resistance. The action of ANP, 
discernable at concentrations of at least 0.1 nM, would suggest a change of total liver blood flow 
in favor of the arterial component (Withrington et aL, 1990). Liver perfusion of rats with ANP 
40 nM, but not with a truncated ANP analog, inhibited hepatic glycolysis and stimulated glucose 
production modestly (Rashed et aL, 1992). These effects seem to be mediated by the B-receptor. 
In rat liver regenerating after partial hepatectomy, the density of ANP binding sites was increased 
2-fold, due to an increase of B- and C-receptors (Nair et aL, 1991). Finally, there is increasing 
evidence for a protective effect of ANP against ischemia/reperfusion damage of perfused rat livers 
(Witthaut et aL, 1992). These effects were observed at 200 nM concentrations of ANP, but not at 
20 nM concentrations, and thus reflect a pharmacological phenomenon rather than a physiological 
action of circulating peptide. 
3. H E M O D Y N A M I C CHANGES A N D PATHOPHYSIOLOGY OF ASCITES 
F O R M A T I O N I N LIVER CIRRHOSIS 
Recently, new concepts have been introduced in the complex pathophysiology of renal sodium 
retention, hemodynamic alterations and ascites formation in liver cirrhosis (Gerbes, 1991). There 
is general acceptance of the pathophysiological importance of the cirrhotic changes in the liver, 
reducing centrally effective blood volume (Henriksen et aL, 1992) by a decrease of the colloid 
osmotic and an increase of the hydrostatic pressure, thus changing Starling forces in the splanchnic 
circulation. This, together with a peripheral vasodilation (Schrier et aL, 1988) activates sodium 
retaining neurohumoral systems, such as the renin-angiotensin-aldosterone and the symphatico-
adrenergic systems contributing to renal sodium retention. There has been an intense search for 
humoral factors involved in vasodilation, sodium retention and, finally, ascites formation in chronic 
liver disease. Years ago, it was postulated that the deficiency of some natriuretic hormone was 
involved in the pathophysiological changes of cirrhosis (Buckalew and Gruber, 1983; Epstein, 1981; 
Kramer, 1975; Naccarato et aL, 1981; De Wardener and Clarkson, 1985). Unfortunately, this 
putative hormone with digoxine-like immunoreactivity has not been identified yet. These unsuccess-
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ful efforts may explain the excitement following the identification of ANP. Therefore, many 
investigations aimed at finding a defect of the ANP system, compatible with a deficiency of 
natriuretic activity and resulting in sodium retention. In this respect, interest has focused on 
determination of plasma concentrations and their dependence on various factors, relation to other 
volume-regulating hormones and to renal function, release into and clearance from the circulation, 
renal and vascular responses to ANP and, finally, the therapeutic potential of ANP. The results 
suggest ANP as another clue to the puzzle, rather than the solution to the problems of 
understanding the pathophysiology of hemodynamic changes and sodium retention in chronic liver 
disease. 
4. ANP I N LIVER DISEASE 
4.1. PLASMA CONCENTRATION , 
The first communication on ANP in patients with cirrhosis of the liver found slightly elevated 
concentrations compared to controls (Gerbes et aL, 1985). Ever since, numerous investigations have 
found mainly normal or elevated plasma concentrations (Gerbes et aL, 1987; Epstein, 1989). 
Recently, it was shown that plasma concentrations of BNP in patients with cirrhosis were elevated 
(La Villa et aL, 1992). Thus, there is no deficiency of circulating natriuretic peptides in patients 
with cirrhosis with or without ascites. In view of the wide range of ANP concentrations reported, 
methodological aspects, as well as the influence of various patient-related factors, are worth 
mentioning. Validation of the radioimmunoassays by recovery experiments, by parallelity of 
dilution curves to the standard curve, by intra- and interassay variation, as well as by character-
ization of the immunoreactivity, seem mandatory for reliable detection. Extraction of plasma prior 
to the radioimmunoassay is indispensable. This can be clearly judged from the results of the 
International Collaborative Study of the proposed international standard for atrial natriuretic 
factor on behalf of the American Heart Association/International Society of Hypertension/World 
Health Organisation.* Unfortunately, this comparison of assays from many laboratories all over 
the world has never been published, due to the lack of consent from some participants. At the 
present time, however, most assays seem suitably standardized and the importance of plasma 
extraction is generally agreed upon. 
Several communications have shown a significant influence of posture, circadian rhythms, diet, 
diuretics, paracentesis or albumin infusion on ANP plasma concentrations. Most investigations of 
neurohumoral systems are performed with the subjects in supine position. While this should allow 
for standardization, it reflects the posture of man during only one-third of the day. Most of the 
time is spent in the sitting and standing positions, which, therefore, should also be considered. In 
our initial observation, we found elevated ANP plasma concentrations in supine patients with 
cirrhosis, but later no significant difference to controls in patients maintaining a sitting position 
(Gerbes et aL, 1985, 1989). Most recently, no difference of ANP plasma concentration was found 
between cirrhotic patients without ascites and controls while standing (Bernardi et aL, 1992). 
Following the assumption of supine position, ANP concentrations increased at 30 min in the 
patients with cirrhosis and at 60 min in the controls, with mean values at 120 min of supine position 
in cirrhosis almost 2-fold those of controls. This was paralleled by a greater decrease of peripheral 
vascular resistance and a greater increase of cardiac output in the group of patients in the horizontal 
posture. Renal sodium excretion, which was reduced in the standing position, increased 3-fold, no 
longer differing from supine controls (Bernardi et aL, 1993). 
These data do not only provide clear evidence for the posture dependence of ANP plasma 
concentrations, but may also suggest an influence of the peptide on peripheral vascular resistance 
and renal sodium excretion of patients with preascitic cirrhosis. Inverse correlations of ANP plasma 
concentration to plasma volume and cardiac output were described by one group (Vinel et aL, 
1989) , but others observed linear correlations to plasma volume and atrial volume (Rector et aL, 
1990) and showed increased natriuresis together with a trend towards increased ANP concen-
*National Institute for Biological Standards and Control, Holly Hill, Hampstead, London, NW3 6RB, 
U.K. (1986) Invitation letter. 
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trations (Panos et aL, 1992). While these authors, as well as another group (Colantonio et aL, 1989), 
failed to detect a significant circadian rhythm of ANP in patients with compensated or decompen-
sated cirrhosis, plasma renin activity and plasma aldosterone concentrations showed more marked 
circadian profiles in patients with cirrhosis than in controls with highest elevations during day time. 
These observations support earlier findings (Trevisani et aL, 1989) of alterations of circadian 
rhythm in patients with hyperaldosteronism correlating to the pattern of renal sodium excretion. 
Thus, both ANP and renin-aldosterone seem to be involved in renal sodium handling of patients 
with cirrhosis. We have, therefore, proposed a ratio of ANP/aldosterone, possibly reflecting 
natriuretic hormonal activities, and found a correlation to baseline as well as to water immersion 
stimulated sodium excretion in patients with and without ascites (Gerbes et aL, 1989). This has been 
confirmed by recent observations (Bernardi et aL, 1993; Angeli et aL, 1992), showing that patients 
with ascites undergoing spontaneous diuresis had higher ANP/plasma renin activity ratios than 
controls. This ratio was also higher in patients responding to diuretic therapy than in non-respon-
ders (Angeli et aL, 1992). 
A N P plasma concentrations in patients with chronic liver disease are influenced by short-term 
changes of sodium intake. On a 100 mmol, as compared to 20 mmol, per day sodium diet, patients 
with cirrhosis and a history of volume retention showed a more marked increase of plasma A N P 
concentration than patients without ascites or controls (Warner et aL, 1990). Furthermore, diuretic 
therapy influences plasma concentrations in patients with ascites. Our preliminary observation 
(Gerbes et aL, 1985) of a decrease of plasma ANP following diuretic therapy was confirmed by 
different groups (Uemura et aL, 1989; Salerno et aL, 1990b). The latter investigators found higher 
than normal ANP plasma concentrations only in patients with ascites not subjected to diuretic 
therapy. Decreases of plasma ANP following hemodialysis and increases following albumin 
infusion were observed in patients with fulminant hepatic failure (Panos et aL, 1991). 
These findings underline the importance of standardizing conditions for determination of 
neurohumoral systems, and especially of ANP, and may explain quite a few discrepancies and 
variations of results obtained by different investigators. Altogether, ANP plasma concentrations 
in cirrhosis are normal or elevated. 
4.2. CHARACTERIZATION OF ANP IMMUNOREACTIVITY 
Despite increased ANP plasma concentrations in cirrhosis, biological activity could be reduced 
with precursor forms or degradation products of ANP, recognized by the immunoassay but 
exhibiting less biologic activity (Arendt et aL, 1987). In a preliminary observation (Arendt et aL, 
1986), the HPLC molecular weight pattern of immunoreactive ANP of patients with cirrhosis did 
not differ significantly from controls. This was confirmed recently (Jimenez et aL, 1991): about 
two-thirds of the ANP immunoreactivity analyzed by chromatography in both cirrhotic patients 
with ascites and healthy subjects coeluted with synthetic ANP 99-126. Moreover, cirrhotic ANP 
displayed the same ability to inhibit the binding of l 2 5I-labelled ANP to rat glomerular and bovine 
adrenal membrane A N P receptors as did synthetic human ANP, Thus, there is no evidence for 
dysregulation of the A N P maturation process in cirrhosis. 
4.3. R E L E A S E INTO AND C L E A R A N C E F R O M THE C I R C U L A T I O N 
ANP plasma concentrations in chronic liver disease different from controls could be due to 
alterations of release and/or clearance. There are discrepant findings in this respect. 
Following central volume expansion by head-out water immersion, healthy subjects showed a 
2-fold increase of A N P plasma concentrations (Gerbes et aL, 1988); this was blunted to about half 
in patients with cirrhosis and ascites (Gerbes et aL, 1989). Similarly, ANP increase upon infusion 
of 500 mL saline solution was smaller in patients with ascites. In contrast, patients with ascites and 
peripheral edema exhibited an exaggerated ANP increase following water immersion (Epstein, 
1989). Increased A N P plasma concentrations in the coronary sinus and higher coronary sinus blood 
flow in patients with cirrhosis and ascites as compared to healthy volunteers, unfortunately not 
matched for age, lead to the estimation of a strikingly increased cardiac release of ANP in cirrhosis 
(Gines et aL, 1988). Several investigations have demonstrated a marked increase of circulating ANP 
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in patients with cirrhosis and ascites following massive central volume expansion, e.g. following 
the implantation of a peritoneo-venous shunt (Klepetko et aL, 1988). For obvious reasons, 
however, this response cannot be compared to that of healthy controls. Altogether, there is no 
clear evidence for alterations of ANP release in patients with cirrhosis. 
Obviously, plasma concentrations of endogenous substances are determined by both release 
and clearance (Gerbes and Vollmar, 1990; Henriksen, 1991). Interestingly, the liver with an 
arterio-venous extraction ratio of about 40% for C-terminal ANP in rats contributes significantly 
to the overall splanchnic ANP extraction (Gerbes et aL, 1992). Thus, liver disease might affect 
hepatic ANP clearance and influence peripheral plasma concentrations. However, splanchnic 
A N P extraction ratio in patients with cirrhosis with or without ascites as well as hepatic-intestinal 
clearance were found to be similar as in controls (Henriksen et aL, 1990, 1993; Tesar et aL, 
1990). Recently, a negative correlation of serum bilirubin concentration and splanchnic ANP 
extraction was found in patients with cirrhosis (Moreau et aL, 1991). Interestingly, 3 of these 11 
subjects exhibiting a very low indocyanine green clearance and presumably very poor splanchnic 
clearance also showed very low peripheral venous as well as arterial ANP concentrations. This 
would allow the conclusion, that some patients with severe cirrhosis and a decreased ANP 
clearance show an even more striking decrease of ANP synthesis, resulting in low peripheral 
venous concentrations. Thus, there is no convincing evidence for changes of splanchnic ANP 
clearance in cirrhosis. 
4.4. R E N A L AND VASCULAR RESPONSE TO ANP 
A number of investigations have demonstrated a blunted renal response to ANP in both 
animal models of cirrhosis as well as in patients (Badalamenti et aL, 1992; Brenard et aL, 
1992; Firth et aL, 1988; Gines et aL, 1992; Laffi et aL, 1989; Lopez et aL, 1989; Mäher et aL, 
1990; Panos et aL, 1990; Salerno et aL, 1990a; Tesar et aL, 1989; Tulassey et aL, 1990). 
Several hypotheses have been offered to explain the reduced renal response to ANP: increased 
activity of the counteracting renin-aldosterone and sympathico-adrenergic systems, ANP-induced 
reduction of renal perfusion pressure, activation of sodium retaining neurohumoral systems upon 
lowering of arterial pressure by ANP, changes of renal ANP receptor status and signal 
transduction. 
Regarding the response to endogenous ANP elevations, the infusion of 2 L of saline solution 
lead to comparable increases of plasma ANP concentrations in 6 controls, 6 patients with and 6 
patients without ascites (Tesar et aL, 1989). This was accompanied by a significant increase in 
urinary flow and sodium excretion in both controls and non-ascitic cirrhotics, but not in patients 
with ascites. Similarly, during head-out water immersion with an increase of plasma ANP 
concentration, patients with cirrhosis and ascites did not show an increase of renal excretion of 
the second messenger cyclic guanosine-mono-phospate (cGMP) (Gerbes et aL, 1989). Following 
the end of immersion, these patients exhibited a decrease of natriuresis despite persistant elevation 
of plasma ANP. 
The response to exogenously administrated ANP seems to be clearly heterogeneous in patients 
with decompensated cirrhosis. A n infusion of 100 ng/min/kg body weight for 45 min following an 
initial bolus of 50 / ig of ANP elicited a remarkable increase in natriuresis in 5 patients with 
cirrhosis and ascites, induced an intermediate response in 4 patients and showed no effect in 6 
patients (Laffi et aL, 1989). Both responders and non-responders showed a significant decrease in 
mean blood pressure, which in the non-responders was followed by a significant increase of 
plasma renin activity and heart rate. The authors, therefore, hypothesized that the natriuretic 
effect of A N P in non-responders was blunted by the hemodynamic and hormonal changes 
triggered by the concommitant ANP induced hypotension. A similar heterogenous response to 
ANP was observed in preascitic bile duct-ligated dogs (Mäher et aL, 1990). ANP administration 
at 175 ng/kg/min induced an increase of sodium excretion in 5 dogs but not in another 4. These 
observations suggest some defect of ANP signal transduction in cirrhosis. 
In several investigations, patients with cirrhosis, following even low dose infusions of ANP, 
showed a marked decrease of mean arterial pressure, e.g. by 18% after 25 ng/kg/min ANP 
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(Brenard et aL, 1992). Therefore, it has been speculated that this further reduction of a lower than 
normal basal blood pressure (Beutler et aL, 1989) in cirrhosis, by reducing renal perfusion pressure 
and stimulating the activity of sodium retaining hormonal systems, could counteract the natriuretic 
effect of ANP (Gerbes et aL, 1989). Furthermore, it could be possible that patients with cirrhosis 
exhibit an exaggerated vascular reactivity that could enhance peripheral vasodilation and further 
reduce the renal response (Salerno et aL, 1990b). To elucidate this question, ANP was combined 
with norepinephrine administration (Badalamenti et aL, 1992; Gines et aL, 1992; Lopez et aL, 1989). 
While urinary flow rate was markedly improved by the coadministration of ANP (1 mg/kg as bolus) 
and norepinephrine, dosed to raise baseline blood pressure by 15-20 mm Hg, there was no 
improvement of sodium excretion (Badalamenti et aL, 1992). In another study, the infusion of 15 
ng/kg/min of ANP prompted no increase of urinary volume nor sodium excretion in 11 of 16 
patients with cirrhosis and ascites (Gines et aL, 1992). In seven of these patients, an infusion o f 
norepinephrine that raised their arterial pressure to the levels of responders did not reverse the 
blunted renal response. These observations point towards a blunted response of the kidney, 
irrespective of systemic blood pressure or renal perfusion pressure. This contention is supported 
by the observation of impaired natriuretic response in the isolated kidneys of rats with experimental 
cirrhosis (Panos et aL, 1990). It seems to be an ANP-specific phenomenon, since isolated kidneys 
from cirrhotic animals showed a normal natriuretic response to stepwise increases in perfusion 
pressure. In normal subjects, a bolus injection (33 μg) of ANP evokes an increase in cGMP plasma 
levels (Heim et aL, 1990) and renal cGMP excretion. Patients with cirrhosis and ascites, however, 
with increased basal plasma cGMP concentrations showed less increase of humoral cGMP 
following endogenous ANP elevations (Pilz, 1991) or following a 30 min infusion of 0.5 μg/kg ANP 
(Miyase et aL, 1990). 
In order to further elucidate the blunted response of the kidney in cirrhosis, the glomerular 
ANP receptor status was investigated. On isolated glomeruli of bile duct ligated rats without 
ascites, density of ANP-binding sites was found to be increased in comparison to sham-operated 
controls (Morgan et aL, 1992). These authors found just one single type of ANP-binding site, which 
was not characterized further. Given the totally different function of the B- and C-receptors for 
ANP, however, quantitative discrimination seems mandatory when searching for functional 
changes. Therefore, we had developed a displacement-binding assay employing ANP, as well as 
a truncated analog binding to C-receptors only for the quantitative discrimination of B- and 
C-receptors (Kollenda et aL, 1991). This was particularly important to resolve the seeming 
contradiction of previous reports (Ballermann et aL, 1985; Cachofeiro et aL, 1989), namely a 
blunted biological response and reduced cGMP generation despite an increase of total glomerular 
ANP receptor density in various conditions. We found a doubling of ANP receptor density 
following water deprivation in rats, entirely due to an increase of C-receptors with no change of 
B-receptors (Kollenda et aL, 1990). Thus, it would seem that changes of the density of the 
C-receptors, involved in the clearance of ANP rather than of the guanylate cyclase coupled 
B-receptors were important in physiologic regulations of the ANP system. We then investigated 
the glomerular receptor status of bile duct ligated rats with cirrhosis and ascites, exhibiting no 
difference in ANP plasma concentrations compared to sham-operated controls. Total glomerular 
ANP receptor density in cirrhotic animals was about twice that of controls, and quantitative 
discrimination showed that this increase was solely due to a doubling of the C-receptor density. 
The reduction of B-receptor density did not reach significance (Gerbes et aL, 1991b). The change 
of ANP receptor status in this model of cirrhosis could thus result in an increased binding of ANP 
to glomerular clearance receptors and in a smaller portion of ANP remaining to bind a slightly 
reduced number of guanylate cyclase coupled receptors. This could contribute to the blunted renal 
effect of ANP in cirrhosis. 
The other component most likely involved in the reduced renal response to ANP is the increased 
activity of sodium retaining neurohumoral systems, as mentioned above. The combination of 
mannitol and ANP infusion could significantly increase renal sodium excretion in patients with 
cirrhosis and ascites not responding to ANP alone (Morali et aL, 1992). Thus, it seems that an 
increased proximal tubular reabsorption of sodium and an increased activity of the 
renin-aldosterone and symphatico-adrenergic systems as seen in these patients might contribute to 
the ANP unresponsiveness in patients with cirrhosis and ascites. 
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4.5. THERAP EU TIC POTENTIAL 
Notwithstanding the above mentioned blunted response to ANP administration, pharmacologi-
cal interventions leading to a minor increase of endogenous ANP in the kidney might have 
therapeutic potential in patients with liver disease and sodium retention. As mentioned before, 
inactivation of A N P is mainly due to two mechanisms: binding to clearance receptors, resulting 
in internalization and catabolism or hydrolysis by ecto-enzymes, in particular enkephalinase (E.C. 
3.4.24.11) (Gerbes and Vollmar, 1990). This ANP-degrading enzyme has been characterized in 
renal tissue. Therefore, enkephalinase inhibition might result in augmented renal ANP effects. A 
single oral dose of Sinorphan, an enkephalinase inhibitor, caused a small increase of plasma ANP 
and cGMP levels in patients with cirrhosis and ascites (Dussaule et aL, 1991). This was followed 
by a slight and transient increase in humoral sodium excretion during a 2 hr period after drug 
administration. Interestingly, plasma aldosterone concentrations decreased significantly. Thus, 
enkephalinase inhibitors would seem an interesting diuretic substance, supressing the 
renin-aldosterone axis by raised endogenous ANP levels rather than activating it as other diuretics 
do. I t has been shown, that infusion of the vasopressin analog ornipressin via hemodynamic effects 
significantly improved renal function in patients with hepato-renal syndrome (Lenz et aL, 1991). 
Possibly the coadministration of enkephalinase inhibitors might be of further benefit for these 
patients with liver disease and severely impaired renal function. 
5. S U M M A R Y 
Following the identification and characterization of ANP, its role in liver disease has been 
laboriously investigated. In particular, potential defects of ANP have been looked for. In patients 
with cirrhosis of the liver with or without ascites, no difference or even an increase of ANP plasma 
concentrations were detected. There is no evidence for circulation of immunoreactive ANP 
products with reduced biological activity in cirrhosis. Following volume stimulation, patients with 
ascites may exhibit a smaller plasma ANP increase than healthy controls. ANP clearance in the 
splanchnic circulation seems not to be affected in cirrhosis. I t is widely accepted that the renal effect 
of endogenous and exogenously administered ANP is blunted in cirrhosis. This may be due to the 
increased activity of counteracting sodium retaining hormonal systems, such as the 
renin-aldosterone and the sympathico-adrenergic systems, as well as to changes of the renal 
receptor status with increased density of clearance receptors. Further investigations will show, 
whether pharmacological inhibition of ANP degradation or clearance may yield a therapeutic 
potential. 
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